Potential Equine Insulin Dysregulation Therapeutic Studied
In a recent study led by Melody de Laat, PhD, from Queensland University of Technology, in Australia, researchers sought to investigate three things:
- The tissue distribution of equine glucose-dependent insulinotropic polypeptide receptors (eGIPR)—receptors found mainly in gut that, when in the presence of glucose molecules, signals an increase in insulin secretion;
- If a GIP antagonist could block eGIPR;
- If a relationship exists between GIP concentration and obesity.
First, the researchers obtained pancreas samples from five healthy mixed-breed horses; they also gathered heart, kidney, lamellae, tongue, skeletal muscle, and duodenum (a part of the small intestine) samples from four healthy horses post-mortem in a previous study.
The team extracted tissue RNA from each sample and produced and sequenced a complementary DNA sample. This allowed them to determine specific gene expression in the various tissues. They confirmed eGIP gene expression in the heart, liver, pancreas, kidney, and duodenum; found very small amounts of eGIP expression in the lamellae and tongue; and observed no evidence of eGIP gene expression in the skeletal
Create a free account with TheHorse.com to view this content.
Stay on top of the most recent Horse Health news with